Patrick B. Johnston, MD, PhD^1*, Amanda F. Cashen, MD², Petros G. Nikolinakos, MD^3*, Anne W Beaven, MD⁴, Stefan Klaus Barta, MD, MRCP, MS⁵, Gajanan Bhat, PhD^6*, Tao Song^7*, Mi Rim Choi, MD⁸, Lee F. Allen, MD, PhD⁸, Sven de Vos, MD, PhD⁹, Yasuhiro Oki, MD¹⁰, Changchun Deng, MD, PhD¹¹ and Francine M Foss, MD¹²

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Division of Oncology, Washington University School of Medicine, St. Louis, MO
³University Cancer and Blood Center, Athens, GA
⁴Hematologic Malignancies, Duke University Medical Center, Durham, NC
⁵Fox Chase Cancer Center, Philadelphia, PA
⁶SPECTRUM PHARMACEUTICALS, INC., Irvine, CA
⁷Spectrum Pharmaceutical, Inc, Irvine, CA
⁸Spectrum Pharmaceuticals, Inc, Irvine, CA
⁹University of California, Los Angeles, Los Angeles, CA
¹⁰Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
¹¹Columbia University Medical Center, New York, NY
¹²Yale Cancer Center, New Haven, CT

John F. Gerecitano, MD¹, Andrew W. Roberts, MBBS, PhD^2,3, John F. Seymour, MBBS, PhD⁴, William G. Wierda, MD^5*, Brad S. Kahl, MD⁶, John M. Pagel, MD, PhD^7*, Soham Puvvada, MD⁸, Thomas J. Kipps, MD, PhD⁹, Mary Ann Anderson, MBBS^2,3*, Martin Dunbar, DrPH^10*, Ming Zhu, PhD^10*, Lori Gressick, BS^10*, Lindsay Wagner, BS^10*, Su Young Kim, MD^10*, Sari Heitner Enschende, MD^10*, Rod A. Humerickhouse, MD, PhD¹⁰ and Matthew S. Davids, MD¹¹

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
³Royal Melbourne Hospital, Melbourne, Australia
⁴Peter MacCallum Cancer Centre, Melbourne, Australia
⁵The University of Texas MD Anderson Cancer Center, Houston, TX
⁶University of Wisconsin, Madison
⁷Swedish Medical Center, Seattle, WA
⁸University of Arizona, Tucson
⁹University of California San Diego, San Diego
¹⁰AbbVie Inc., North Chicago, IL
¹¹Dana-Farber Cancer Institute, Boston, MA

Sven de Vos, MD, PhD¹, Lode Swinnen, MD², Mark Kozloff, MD^3*, Ding Wang, MD, PhD^4*, Erin Reid, MD⁵, Loretta Nastoupil, MD⁶, Nathan Fowler, MD⁷, Jaclyn Cordero^8*, Diane D'Amico^8*, Susan Diehl^8*, Martin Dunbar, DrPH^8*, Ming Zhu, PhD^8*, Shekman Wong, PhD^8*, Sari Heitner Enschede, MD^8*, David Chien, MD^8*, Rod A. Humerickhouse, MD, PhD⁸ and Christopher Flowers, MD⁹

¹University of California, Los Angeles, Los Angeles, CA
²Johns Hopkins University, Baltimore, MD
³Ingalls Memorial Hospital, Harvey, IL
⁴Henry Ford Hospital, Detroit, MI
⁵University of California San Diego, La Jolla, CA
⁶University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸AbbVie Inc., North Chicago, IL
⁹Winship Cancer Institute of Emory University, Atlanta, GA

Vincent Ribrag, MD¹, Won Seog Kim, MD, PhD^2*, Reda Bouabdallah, MD³, Soon Thye Lim, MBBS, MRCP^4*, Bertrand Coiffier, MD, PhD⁵, Zakia Felloussi^6*, Ioana Kloos^6*, Ying Luan, PhD^7*, Thorsten Graef, MD, PhD⁷ and Franck Morschhauser, MD^8*

¹DITEP/medicine, Gustave Roussy Cancer Campus, Villejuif, France
²Samsung Medical Center, Seoul, South Korea
³CLCC Institut Paoli Calmettes, Marseille, France
⁴National Cancer Center Singapore, Singapore, Singapore
⁵Hospices Civils de Lyon, Lyon, France
⁶Servier, Paris, France
⁷Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
⁸Hematology Department, Centre Hospitalier Régional Universitaire de Lille, Lille, France

Anas Younes, MD¹, Jesus G. Berdeja, MD², Manish R. Patel, MD³, Kevin R. Kelly, MD, PhD⁴, Ian W. Flinn, MD, PhD², John F Gerecitano, MD, PhD¹, Sattva S. Neelapu, MD⁵, Amanda R. Copeland, RN, MSN, CNS^1*, Amy Akins, RN, BSN, CCRC^3*, Myles Clancy^6*, Anna Ma, MS^6*, Kaiming Sun, PhD^6*, Ze Tian, PhD^6*, Jing Wang, PhD^6*, Jaye Viner, MD, MPH⁶ and Yasuhiro Oki, MD⁵

¹Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Sarah Cannon Research Institute, Nashville, TN
³Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL
⁴University of Southern California Keck School of Medicine, Los Angeles, CA
⁵Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Curis, Lexington, MA

Christine Chen, MD¹, Ramiro Garzon, MD², Martin Gutierrez^3*, Meagan A. Jacoby, MD, PhD⁴, Peter Brown^5*, Ian Flinn^6*, Richard M. Stone, MD⁷, Mary Lynn Savoie, MD⁸, Rachid Baz⁹, Nashat Y. Gabrail, MD^10*, Michael Wang, MD¹¹, Peter Martin, MD¹², David S Siegel, MD, PhD¹³, Morten Mau-Sřrensen^5*, Michael Andreef^14*, Tracey Marshall^15*, Jean-Richard Saint-Martin^15*, Robert Carlson^15*, Sharon Shacham^16*, Michael Kauffman^15* and John Kuruvilla, MD¹⁷

¹Princess Margaret Hospital, Toronto, ON, Canada
²The Ohio State University, Columbus, OH
³John Theurer Cancer Center, Hackensack, NJ
⁴Department of Medicine, Division of Oncology, Washington University in St. Louis, Saint Louis, MO
⁵Rigshospitalet University Hospital, Copenhagen, Denmark
⁶Sarah Cannon Research Institute, Nashville, TN
⁷Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁸University of Calgary, Calgary, Canada
⁹Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁰Gabrail Cancer Center, Canton, OH
¹¹Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY
¹³Hackensack University Medical Center, John Theurer Cancer Center, Hackensack, NJ
¹⁴MD Anderson Cancer Center, Houston, TX
¹⁵Karyopharm Therapeutics, Newton, MA
¹⁶Karyopharm Therapeutics, Inc, Newton, MA
¹⁷Division of Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada